Submission for OMB Review; 30-Day Comment Request; Population Assessment of Tobacco and Health (PATH) Study-Fourth Wave of Data Collection, 43217-43219 [2016-15644]
Download as PDF
<![CDATA[
Federal Register / Vol. 81, No. 127 / Friday, July 1, 2016 / Notices
and Clinicians; 93.272, Alcohol National
Research Service Awards for Research
Training; 93.273, Alcohol Research Programs;
93.891, Alcohol Research Center Grants;
93.701, ARRA Related Biomedical Research
and Research Support Awards, National
Institutes of Health, HHS)
Dated: June 27, 2016.
Jennifer Spaeth,
Director, Office of Federal Advisory
Committee Policy.
[FR Doc. 2016–15643 Filed 6–30–16; 8:45 am]
BILLING CODE 4140–01–P
Dated: June 27, 2016.
Melanie J. Gray,
Program Analyst, Office of Federal Advisory
Committee Policy.
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
[FR Doc. 2016–15592 Filed 6–30–16; 8:45 am]
BILLING CODE 4140–01–P
National Institute on Alcohol Abuse
and Alcoholism; Notice of Closed
Meetings
asabaliauskas on DSK3SPTVN1PROD with NOTICES
Pursuant to section 10(d) of the
Federal Advisory Committee Act, as
amended (5 U.S.C. App.), notice is
hereby given of the following meetings.
The meetings will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,
as amended. The grant applications and
the discussions could disclose
confidential trade secrets or commercial
property such as patentable material,
and personal information concerning
individuals associated with the grant
applications, the disclosure of which
would constitute a clearly unwarranted
invasion of personal privacy.
Name of Committee: National Institute on
Alcohol Abuse and Alcoholism Special
Emphasis Panel; NIAAA Member Conflict
Reviews—Clinical Sciences and
Epidemiology.
Date: July 11, 2016.
Time: 11:00 a.m. to 3:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institutes of Health–
NIAAA, 5635 Fishers Lane, Rockville, MD
20892 (Telephone Conference Call).
Contact Person: Richard A. Rippe, Ph.D.,
Scientific Review Officer, National Institute
on Alcohol Abuse and Alcoholism, National
Institutes of Health, 5635 Fishers Lane, Room
2109, Rockville, MD 20852, 301–443–8599,
rippera@mail.nih.gov.
Name of Committee: National Institute on
Alcohol Abuse and Alcoholism Special
Emphasis Panel; NIAAA Fellowship Review.
Date: July 26, 2016.
Time: 8:00 a.m. to 3:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institutes of Health,
National Institute on Alcohol Abuse and
Alcoholism, Terrace Level Conference Room
508, 5635 Fishers LN, Rockville, MD 20892.
Contact Person: Richard A. Rippe, Ph.D.,
Scientific Review Officer, National Institute
on Alcohol Abuse and Alcoholism, National
Institutes of Health, 5635 Fishers Lane, Room
2109, Rockville, MD 20852, 301–443–8599,
rippera@mail.nih.gov.
(Catalogue of Federal Domestic Assistance
Program Nos. 93.271, Alcohol Research
Career Development Awards for Scientists
VerDate Sep<11>2014
19:05 Jun 30, 2016
Jkt 238001
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
National Cancer Institute; Cancellation
of Meeting
Notice is hereby given of the
cancellation of the National Cancer
Institute Special Emphasis Panel, June
27, 2016, 11:00 a.m. to June 27, 2016,
12:00 p.m., National Cancer Institute
Shady Grove, 9609 Medical Center
Drive, 7W624, Rockville, MD, 20850
which was published in the Federal
Register on May 2, 2016, 81FR26240.
This meeting is canceled because the
applications were reassigned.
Dated: June 27, 2016.
Melanie J. Gray,
Program Analyst, Office of Federal Advisory
Committee Policy.
[FR Doc. 2016–15591 Filed 6–30–16; 8:45 am]
BILLING CODE 4140–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
43217
Name of Committee: National Institute on
Alcohol Abuse and Alcoholism Special
Emphasis Panel; U01 Application Review.
Date: July 13, 2016.
Time: 11:00 a.m. to 3:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institutes of Health,
National Institute on Alcohol Abuse and
Alcoholism, 5635 Fishers Lane, Rockville,
MD 20892, (Telephone Conference Call).
Contact Person: Richard A. Rippe, Ph.D.,
Scientific Review Officer, National Institute
on Alcohol Abuse and Alcoholism, 5635
Fishers Lane, Room 2109, Rockville, MD
20852, 301–443–8599, rippera@mail.nih.gov.
Name of Committee: National Institute on
Alcohol Abuse and Alcoholism Special
Emphasis Panel; Targets of Low Dose
Alcohol in the Brain.
Date: July 21, 2016.
Time: 8:00 a.m. to 5:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institutes of Health,
National Institute on Alcohol Abuse and
Alcoholism, Conference Room 3002/3004,
5635 Fishers Lane, Rockville, MD 20892.
Contact Person: Philippe Marmillot, Ph.D.,
National Institutes of Health, National
Institute on Alcohol Abuse and Alcoholism,
5635 Fishers Lane, Rm 2017, Bethesda, MD
20892, 301–443–2861, marmillotp@
mail.nih.gov.
(Catalogue of Federal Domestic Assistance
Program Nos. 93.271, Alcohol Research
Career Development Awards for Scientists
and Clinicians; 93.272, Alcohol National
Research Service Awards for Research
Training; 93.273, Alcohol Research Programs;
93.891, Alcohol Research Center Grants;
93.701, ARRA Related Biomedical Research
and Research Support Awards, National
Institutes of Health, HHS)
Dated: June 27, 2016.
Melanie J. Gray,
Program Analyst, Office of Federal Advisory
Committee Policy.
[FR Doc. 2016–15593 Filed 6–30–16; 8:45 am]
National Institutes of Health
BILLING CODE 4140–01–P
National Institute on Alcohol Abuse
And Alcoholism; Notice of Closed
Meetings
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Pursuant to section 10(d) of the
Federal Advisory Committee Act, as
amended (5 U.S.C. App.), notice is
hereby given of the following meetings.
The meetings will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,
as amended. The grant applications and
the discussions could disclose
confidential trade secrets or commercial
property such as patentable material,
and personal information concerning
individuals associated with the grant
applications, the disclosure of which
would constitute a clearly unwarranted
invasion of personal privacy.
PO 00000
Frm 00036
Fmt 4703
Sfmt 4703
National Institutes of Health
Submission for OMB Review; 30-Day
Comment Request; Population
Assessment of Tobacco and Health
(PATH) Study—Fourth Wave of Data
Collection
AGENCY:
National Institute of Health,
HHS.
Under the provisions of
Section 3507(a)(1)(D) of the Paperwork
Reduction Act of 1995, the National
Institutes of Health (NIH) has submitted
to the Office of Management and Budget
(OMB) a request for review and
approval of the information collection
listed below. This proposed information
SUMMARY:
E:\FR\FM\01JYN1.SGM
01JYN1
43218
Federal Register / Vol. 81, No. 127 / Friday, July 1, 2016 / Notices
collection was previously published in
the Federal Register on April 15, 2016,
pages 22290—22291 and allowed 60days for public comment. No public
comments were received. The purpose
of this notice is to allow an additional
30 days for public comment. The
National Institutes of Health may not
conduct or sponsor, and the respondent
is not required to respond to, an
information collection that has been
extended, revised, or implemented on or
after October 1, 1995, unless it displays
a currently valid OMB control number.
Direct Comments To OMB: Written
comments and/or suggestions regarding
the item(s) contained in this notice,
especially regarding the estimated
public burden and associated response
time, should be directed to the: Office
of Management and Budget, Office of
Regulatory Affairs,
OIRA_Submission@omb.eop.gov or by
fax to (202) 395–6974, Attention: NIH
Desk Officer.
Comment Due Date: Comments
regarding this information collection are
best assured of having their full effect if
received within 30 days of the date of
this publication.
FOR FURTHER INFORMATION CONTACT: To
obtain a copy of the data collection
plans and instruments, submit
comments in writing or request more
information on the proposed project,
contact: Kevin P. Conway, Ph.D.,
Deputy Director, Division of
Epidemiology, Services, and Prevention
Research, National Institute on Drug
Abuse, 6001 Executive Boulevard, Room
5185; or call non-toll-free number (301)
443–8755; or Email your request,
including your address to:
PATHprojectofficer@mail.nih.gov.
Formal requests for additional plans and
instruments must be requested in
writing.
Proposed Collection: Population
Assessment of Tobacco and Health
(PATH) Study—Fourth Wave of Data
Collection (NIDA), 0925–0664,
expiration date 8/31/2018—
REVISION—NIDA, NIH, in partnership
with the Food and Drug Administration
(FDA).
Need and Use of Information
Collection: This is a revision request
(OMB number 0925–0664, expiration
date 8/31/2018) for the Population
Assessment of Tobacco and Health
(PATH) Study to conduct the fourth
wave of data collection. The PATH
Study is a large national longitudinal
cohort study on tobacco use behavior
and health among the U.S. household
population of adults age 18 and older
and youth ages 12 to 17. On an annual
basis, the PATH Study conducts
interviews with and collects
biospecimens from adults and youth to
help inform the development,
implementation, and evaluation of
tobacco-product regulations by FDA in
meeting its mission under the Family
Smoking Prevention and Tobacco
Control Act (TCA) to regulate tobacco
products, including tobacco-product
advertising, labeling, marketing,
constituents, ingredients, and additives.
The longitudinal design of the PATH
Study provides it with the capacity to
measure and report within-person
changes and between-person differences
in tobacco product use behaviors and
health effects within the cohort over
time. These data will help to inform
regulatory decisions and actions by FDA
and FDA’s evaluations of associations
between its regulations and tobacco use
behaviors and health indicators in the
population.
OMB approval is requested for 3
years. There are no costs to respondents
other than their time. The total
estimated annualized burden hours are
94,798.
ESTIMATED ANNUALIZED BURDEN HOURS
Households ........................................................
Adults—New adults ...........................................
Adults—New adults and Wave 1 youth respondents who age up to adult cohort at
Wave 4.
Adults—Adult respondents at previous wave ....
Adults—Parents of new youth and parents of
shadow youth who age up to youth cohort at
Wave 4.
Adults—Parents of youth respondents at previous wave.
Youth—New youth and shadow youth who age
up to youth cohort at Wave 4.
Youth—Youth respondents at previous wave ...
Adults .................................................................
Youth ..................................................................
Households ........................................................
Adults .................................................................
Adults .................................................................
Adults—New adults and Wave 1 youth respondents who age up to adult cohort at
Wave 4.
Adults .................................................................
Youth ..................................................................
Adults .................................................................
48,018
9,152
10,737
1
1
1
14/60
6/60
68/60
11,204
915
12,169
23,414
6,561
1
1
1
19/60
23,414
2,078
8,800
1
16/60
2,347
6,432
1
45/60
4,824
8,627
23,133
10,239
41,207
33,889
301
4,832
1
1
1
1
1
1
1
35/60
5/60
5/60
5/60
2/60
4/60
18/60
5,032
1,928
853
3,434
1,130
20
1,450
18,301
10,239
34,151
1
1
2
10/60
10/60
8/60
3,050
1,707
9,107
Adults—Parents of youth respondents ..............
15,059
2
8/60
4,016
1. Household Screener ...................
2. Individual Screener .....................
3. Extended Interview ......................
6. Parent Interview ..........................
7. Extended Interview ......................
asabaliauskas on DSK3SPTVN1PROD with NOTICES
8. Extended Interview ......................
9. Tobacco Use Form .....................
10. Tobacco Use Form ...................
11. Shadow Youth Only Screener ..
12. Verification Interview .................
13. Validation Interview ...................
14. Biospecimen Collection: Blood
15. Biospecimen Collection: Urine ..
16. Biospecimen Collection: Urine ..
17. Follow-up/Tracking Participant
Information Form.
18. Follow-up/Tracking Participant
Information Form for Youth (completed by parents).
VerDate Sep<11>2014
19:05 Jun 30, 2016
Total
annual
burden
hours
Number of
responses per
respondent
Type of respondent
4. Extended Interview ......................
5. Parent Interview ..........................
Average
burden per
response
(in hours)
Number of
respondents
Form name
Jkt 238001
PO 00000
Frm 00037
Fmt 4703
Sfmt 4703
E:\FR\FM\01JYN1.SGM
01JYN1
43219
Federal Register / Vol. 81, No. 127 / Friday, July 1, 2016 / Notices
ESTIMATED ANNUALIZED BURDEN HOURS—Continued
Average
burden per
response
(in hours)
Total
annual
burden
hours
Number of
respondents
Number of
responses per
respondent
Adults—Parents of shadow youth .....................
4,684
2
8/60
1,249
13,984
1
4/60
932
7,657
1
5/60
638
7,657
1
3/60
383
10,737
1
5/60
895
24. Parent permission for urine collection.
25. Assent for urine collection .........
Adults—New adults and Wave 1 youth respondents who age up to adult cohort at
Wave 4.
Adults—Parents of new youth and parents of
Shadow youth who age up to youth cohort at
Wave 4.
Youth—New youth and shadow youth who age
up to youth cohort at Wave 4.
Adults—New adults and Wave 1 youth respondents who age up to adult cohort at
Wave 4.
Adults—Parents of youth respondents at previous wave.
Youth ..................................................................
15,360
1
3/60
768
15,059
1
5/60
1,255
Total .........................................
............................................................................
388,229
442,123
....................
94,798
Form name
Type of respondent
19. Follow-up/Tracking Participant
Information Form for sample
shadow youth (completed by parents).
20. Consent for Extended Interview
21. Parent Permission and Consent
for Parent Interview.
22. Assent for Extended Interview ..
23. Consent for Biological Samples
Dated: June 27, 2016.
Genevieve deAlmeida,
Project Clearance Liaison, National Institute
on Drug Abuse, NIH.
[FR Doc. 2016–15644 Filed 6–30–16; 8:45 am]
BILLING CODE 4140–01–P
DEPARTMENT OF HOMELAND
SECURITY
U.S. Customs and Border Protection
Notice of Issuance of Final
Determination Concerning Certain
Network Cables and Transceivers
U.S. Customs and Border
Protection, Department of Homeland
Security.
ACTION: Notice of final determination.
AGENCY:
This document provides
notice that U.S. Customs and Border
Protection (‘‘CBP’’) has issued a final
determination concerning the country of
origin of certain transceivers imported
separately and certain imported network
cables containing transceivers. Based
upon the facts presented, CBP has
concluded in both instances that the
country of origin of the merchandise is
China for purposes of U.S. Government
procurement.
DATES: The final determination was
issued on June 14, 2016. A copy of the
final determination is attached. Any
party-at-interest, as defined in 19 CFR
177.22(d), may seek judicial review of
this final determination within August
1, 2016.
asabaliauskas on DSK3SPTVN1PROD with NOTICES
SUMMARY:
VerDate Sep<11>2014
19:05 Jun 30, 2016
Jkt 238001
FOR FURTHER INFORMATION CONTACT:
Grace A. Kim, Valuation and Special
Programs Branch, Regulations and
Rulings, Office of International Trade
(202) 325–7941.
SUPPLEMENTARY INFORMATION: Notice is
hereby given that on June 14, 2016,
pursuant to subpart B of Part 177, U.S.
Customs and Border Protection
Regulations (19 CFR part 177, subpart
B), CBP issued a final determination
concerning the country of origin of
certain network cables and transceivers,
which may be offered to the U.S.
Government under an undesignated
government procurement contract. This
final determination, HQ H273091, was
issued under procedures set forth at 19
CFR part 177, subpart B, which
implements Title III of the Trade
Agreements Act of 1979, as amended
(19 U.S.C. 2511–18). In the final
determination, CBP concluded that the
processing of the imported merchandise
in the U.S. does not result in a
substantial transformation. Therefore,
the country of origin of the transceivers
and of the network cables containing
transceivers is China for purposes of
U.S. Government procurement.
Section 177.29, CBP Regulations (19
CFR 177.29), provides that a notice of
final determination shall be published
in the Federal Register within 60 days
of the date the final determination is
issued. Section 177.30, CBP Regulations
(19 CFR 177.30), provides that any
party-at-interest, as defined in 19 CFR
177.22(d), may seek judicial review of a
final determination within 30 days of
publication of such determination in the
Federal Register.
PO 00000
Frm 00038
Fmt 4703
Sfmt 4703
Dated: June 14, 2016.
Joanne R. Stump,
Acting Executive Director, Regulations and
Rulings, Office of International Trade.
HQ H273091
June 14, 2016
OT:RR:CTF:VS H273091 GaK
CATEGORY: Origin
Janet C. Wallett
FCI USA LLC.
825 Old Trail Road
Etters, PA 17319
RE: U.S. Government Procurement; Country
of origin of copper cables containing
transceivers and of the fiber optic
transceiver; Substantial Transformation
Dear Ms. Wallett:
This is in response to your letter dated
January 6, 2016, requesting a final
determination on behalf of FCI USA LLC
(‘‘FCI’’), pursuant to subpart B of part 177 of
the U.S. Customs & Border Protection
(‘‘CBP’’) Regulations (19 CFR part 177).
Under these regulations, which implement
Title III of the Trade Agreements Act of 1979
(‘‘TAA’’), as amended (19 U.S.C. § 2511 et
seq.), CBP issues country of origin advisory
rulings and final determinations as to
whether an article is or would be a product
of a designated country or instrumentality for
the purposes of granting waivers of certain
‘‘Buy American’’ restrictions in U.S. law or
practice for products offered for sale to the
U.S. Government. This final determination
concerns the country of origin of FCI’s
Copper Direct Attach Copper (‘‘DAC’’)
cable—HPL500 (‘‘Cable’’) and Fiber Optic
Transceivers—HPL512 (‘‘Transceivers’’). We
note that as a U.S. importer, FCI is a partyat-interest within the meaning of 19 CFR
§ 177.22(d)(1) and is entitled to request this
final determination.
E:\FR\FM\01JYN1.SGM
01JYN1
]]>Agencies
[Federal Register Volume 81, Number 127 (Friday, July 1, 2016)]
[Notices]
[Pages 43217-43219]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2016-15644]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
National Institutes of Health
Submission for OMB Review; 30-Day Comment Request; Population
Assessment of Tobacco and Health (PATH) Study--Fourth Wave of Data
Collection
AGENCY: National Institute of Health, HHS.
SUMMARY: Under the provisions of Section 3507(a)(1)(D) of the Paperwork
Reduction Act of 1995, the National Institutes of Health (NIH) has
submitted to the Office of Management and Budget (OMB) a request for
review and approval of the information collection listed below. This
proposed information
[[Page 43218]]
collection was previously published in the Federal Register on April
15, 2016, pages 22290--22291 and allowed 60-days for public comment. No
public comments were received. The purpose of this notice is to allow
an additional 30 days for public comment. The National Institutes of
Health may not conduct or sponsor, and the respondent is not required
to respond to, an information collection that has been extended,
revised, or implemented on or after October 1, 1995, unless it displays
a currently valid OMB control number.
Direct Comments To OMB: Written comments and/or suggestions
regarding the item(s) contained in this notice, especially regarding
the estimated public burden and associated response time, should be
directed to the: Office of Management and Budget, Office of Regulatory
Affairs, OIRA_Submission@omb.eop.gov or by fax to (202) 395-6974,
Attention: NIH Desk Officer.
Comment Due Date: Comments regarding this information collection
are best assured of having their full effect if received within 30 days
of the date of this publication.
FOR FURTHER INFORMATION CONTACT: To obtain a copy of the data
collection plans and instruments, submit comments in writing or request
more information on the proposed project, contact: Kevin P. Conway,
Ph.D., Deputy Director, Division of Epidemiology, Services, and
Prevention Research, National Institute on Drug Abuse, 6001 Executive
Boulevard, Room 5185; or call non-toll-free number (301) 443-8755; or
Email your request, including your address to:
PATHprojectofficer@mail.nih.gov. Formal requests for additional plans
and instruments must be requested in writing.
Proposed Collection: Population Assessment of Tobacco and Health
(PATH) Study--Fourth Wave of Data Collection (NIDA), 0925-0664,
expiration date 8/31/2018--REVISION--NIDA, NIH, in partnership with the
Food and Drug Administration (FDA).
Need and Use of Information Collection: This is a revision request
(OMB number 0925-0664, expiration date 8/31/2018) for the Population
Assessment of Tobacco and Health (PATH) Study to conduct the fourth
wave of data collection. The PATH Study is a large national
longitudinal cohort study on tobacco use behavior and health among the
U.S. household population of adults age 18 and older and youth ages 12
to 17. On an annual basis, the PATH Study conducts interviews with and
collects biospecimens from adults and youth to help inform the
development, implementation, and evaluation of tobacco-product
regulations by FDA in meeting its mission under the Family Smoking
Prevention and Tobacco Control Act (TCA) to regulate tobacco products,
including tobacco-product advertising, labeling, marketing,
constituents, ingredients, and additives. The longitudinal design of
the PATH Study provides it with the capacity to measure and report
within-person changes and between-person differences in tobacco product
use behaviors and health effects within the cohort over time. These
data will help to inform regulatory decisions and actions by FDA and
FDA's evaluations of associations between its regulations and tobacco
use behaviors and health indicators in the population.
OMB approval is requested for 3 years. There are no costs to
respondents other than their time. The total estimated annualized
burden hours are 94,798.
Estimated Annualized Burden Hours
----------------------------------------------------------------------------------------------------------------
Average Total
Number of Number of burden per annual
Form name Type of respondent respondents responses per response burden
respondent (in hours) hours
----------------------------------------------------------------------------------------------------------------
1. Household Screener............ Households.............. 48,018 1 14/60 11,204
2. Individual Screener........... Adults--New adults...... 9,152 1 6/60 915
3. Extended Interview............ Adults--New adults and 10,737 1 68/60 12,169
Wave 1 youth
respondents who age up
to adult cohort at Wave
4.
4. Extended Interview............ Adults--Adult 23,414 1 1 23,414
respondents at previous
wave.
5. Parent Interview.............. Adults--Parents of new 6,561 1 19/60 2,078
youth and parents of
shadow youth who age up
to youth cohort at Wave
4.
6. Parent Interview.............. Adults--Parents of youth 8,800 1 16/60 2,347
respondents at previous
wave.
7. Extended Interview............ Youth--New youth and 6,432 1 45/60 4,824
shadow youth who age up
to youth cohort at Wave
4.
8. Extended Interview............ Youth--Youth respondents 8,627 1 35/60 5,032
at previous wave.
9. Tobacco Use Form.............. Adults.................. 23,133 1 5/60 1,928
10. Tobacco Use Form............. Youth................... 10,239 1 5/60 853
11. Shadow Youth Only Screener... Households.............. 41,207 1 5/60 3,434
12. Verification Interview....... Adults.................. 33,889 1 2/60 1,130
13. Validation Interview......... Adults.................. 301 1 4/60 20
14. Biospecimen Collection: Blood Adults--New adults and 4,832 1 18/60 1,450
Wave 1 youth
respondents who age up
to adult cohort at Wave
4.
15. Biospecimen Collection: Urine Adults.................. 18,301 1 10/60 3,050
16. Biospecimen Collection: Urine Youth................... 10,239 1 10/60 1,707
17. Follow-up/Tracking Adults.................. 34,151 2 8/60 9,107
Participant Information Form.
18. Follow-up/Tracking Adults--Parents of youth 15,059 2 8/60 4,016
Participant Information Form for respondents.
Youth (completed by parents).
[[Page 43219]]
19. Follow-up/Tracking Adults--Parents of 4,684 2 8/60 1,249
Participant Information Form for shadow youth.
sample shadow youth (completed
by parents).
20. Consent for Extended Adults--New adults and 13,984 1 4/60 932
Interview. Wave 1 youth
respondents who age up
to adult cohort at Wave
4.
21. Parent Permission and Consent Adults--Parents of new 7,657 1 5/60 638
for Parent Interview. youth and parents of
Shadow youth who age up
to youth cohort at Wave
4.
22. Assent for Extended Interview Youth--New youth and 7,657 1 3/60 383
shadow youth who age up
to youth cohort at Wave
4.
23. Consent for Biological Adults--New adults and 10,737 1 5/60 895
Samples. Wave 1 youth
respondents who age up
to adult cohort at Wave
4.
24. Parent permission for urine Adults--Parents of youth 15,360 1 3/60 768
collection. respondents at previous
wave.
25. Assent for urine collection.. Youth................... 15,059 1 5/60 1,255
----------------------------------------------------
Total........................ ........................ 388,229 442,123 ........... 94,798
----------------------------------------------------------------------------------------------------------------
Dated: June 27, 2016.
Genevieve deAlmeida,
Project Clearance Liaison, National Institute on Drug Abuse, NIH.
[FR Doc. 2016-15644 Filed 6-30-16; 8:45 am]
BILLING CODE 4140-01-P
